1e7i › Citations

Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin.

Bhattacharya AA, Grüne T, Curry S
J Mol Biol 303 721-32 (2000)
Related entries: 1e7e, 1e7f, 1e7g, 1e7h

Cited: 426 times
EuropePMC logo PMID: 11061971

Abstract

Human serum albumin (HSA) is an abundant plasma protein that is responsible for the transport of fatty acids. HSA also binds and perturbs the pharmacokinetics of a wide range of drug compounds. Binding studies have revealed significant interactions between fatty acid and drug-binding sites on albumin but high-resolution structural information on ligand binding to the protein has been lacking. We report here a crystallographic study of five HSA-fatty acid complexes formed using saturated medium-chain and long-chain fatty acids (C10:0, C12:0, C14:0, C16:0 and C18:0). A total of seven binding sites that are occupied by all medium-chain and long-chain fatty acids have been identified, although medium-chain fatty acids are found to bind at additional sites on the protein, yielding a total of 11 distinct binding locations. Comparison of the different complexes reveals key similarities and significant differences in the modes of binding, and serves to rationalise much of the biochemical data on fatty acid interactions with albumin. The two principal drug-binding sites, in sub-domains IIA and IIIA, are observed to be occupied by fatty acids and one of them (in IIIA) appears to coincide with a high-affinity long-chain fatty acid binding site.

Reviews - 1e7i mentioned but not cited (5)

  1. Albumin in decompensated cirrhosis: new concepts and perspectives. Bernardi M, Angeli P, Claria J, Moreau R, Gines P, Jalan R, Caraceni P, Fernandez J, Gerbes AL, O'Brien AJ, Trebicka J, Thevenot T, Arroyo V. Gut 69 1127-1138 (2020)
  2. Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis. Schon HT, Bartneck M, Borkham-Kamphorst E, Nattermann J, Lammers T, Tacke F, Weiskirchen R. Front Pharmacol 7 33 (2016)
  3. Engineering at the nano-bio interface: harnessing the protein corona towards nanoparticle design and function. Pinals RL, Chio L, Ledesma F, Landry MP. Analyst 145 5090-5112 (2020)
  4. Deciphering albumin-directed drug delivery by imaging. Hu H, Quintana J, Weissleder R, Parangi S, Miller M. Adv Drug Deliv Rev 185 114237 (2022)
  5. Influence of zinc on glycosaminoglycan neutralisation during coagulation. Sobczak AIS, Pitt SJ, Stewart AJ. Metallomics 10 1180-1190 (2018)

Articles - 1e7i mentioned but not cited (22)

  1. Interdomain zinc site on human albumin. Stewart AJ, Blindauer CA, Berezenko S, Sleep D, Sadler PJ. Proc Natl Acad Sci U S A 100 3701-3706 (2003)
  2. Hot Spot-Localized Artificial Antibodies for Label-Free Plasmonic Biosensing. Abbas A, Tian L, Morrissey JJ, Kharasch ED, Singamaneni S. Adv Funct Mater 23 1789-1797 (2013)
  3. Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. Li R, Ng TSC, Wang SJ, Prytyskach M, Rodell CB, Mikula H, Kohler RH, Garlin MA, Lauffenburger DA, Parangi S, Dinulescu DM, Bardeesy N, Weissleder R, Miller MA. Nat Nanotechnol 16 830-839 (2021)
  4. Rapid determination of quaternary protein structures in complex biological samples. Hauri S, Khakzad H, Happonen L, Teleman J, Malmström J, Malmström L. Nat Commun 10 192 (2019)
  5. Modulation of the reactivity of the thiol of human serum albumin and its sulfenic derivative by fatty acids. Torres MJ, Turell L, Botti H, Antmann L, Carballal S, Ferrer-Sueta G, Radi R, Alvarez B. Arch Biochem Biophys 521 102-110 (2012)
  6. Evidence for water-tuned structural differences in proteins: an approach emphasizing variations in local hydrophilicity. Akdogan Y, Reichenwallner J, Hinderberger D. PLoS One 7 e45681 (2012)
  7. Characterization of protein immobilization on nanoporous gold using atomic force microscopy and scanning electron microscopy. Tan YH, Schallom JR, Ganesh NV, Fujikawa K, Demchenko AV, Stine KJ. Nanoscale 3 3395-3407 (2011)
  8. Determining biophysical protein stability in lysates by a fast proteolysis assay, FASTpp. Minde DP, Minde DP, Maurice MM, Rüdiger SG. PLoS One 7 e46147 (2012)
  9. Characterization of the solution structure of human serum albumin loaded with a metal porphyrin and fatty acids. Junk MJ, Spiess HW, Hinderberger D. Biophys J 100 2293-2301 (2011)
  10. Mapping hydrophobicity on the protein molecular surface at atom-level resolution. Nicolau DV, Paszek E, Fulga F, Nicolau DV. PLoS One 9 e114042 (2014)
  11. Entropy-driven translocation of disordered proteins through the Gram-positive bacterial cell wall. Halladin DK, Ortega FE, Ng KM, Footer MJ, Mitić NS, Malkov SN, Gopinathan A, Huang KC, Theriot JA. Nat Microbiol 6 1055-1065 (2021)
  12. Lasso-grafting of macrocyclic peptide pharmacophores yields multi-functional proteins. Mihara E, Watanabe S, Bashiruddin NK, Nakamura N, Matoba K, Sano Y, Maini R, Yin Y, Sakai K, Arimori T, Matsumoto K, Suga H, Takagi J. Nat Commun 12 1543 (2021)
  13. Rapid Investigation and Screening of Bioactive Components in Simo Decoction via LC-Q-TOF-MS and UF-HPLC-MD Methods. He Y, Cheng P, Wang W, Yan S, Tang Q, Liu D, Xie H. Molecules 23 E1792 (2018)
  14. Molecular docking, a tool to determine interaction of CuO and TiO 2 nanoparticles with human serum albumin. Chibber S, Ahmad I. Biochem Biophys Rep 6 63-67 (2016)
  15. Synergistic sequence contributions bias glycation outcomes. McEwen JM, Fraser S, Guir ALS, Dave J, Scheck RA. Nat Commun 12 3316 (2021)
  16. Online monitoring of immunoaffinity-based depletion of high-abundance blood proteins by UV spectrophotometry using enhanced green fluorescence protein and FITC-labeled human serum albumin. Kim K, Yu J, Min H, Kim H, Kim B, Yu HG, Kim Y. Proteome Sci 8 62 (2010)
  17. Identification of Patients with Pancreatic Cancer by Electron Paramagnetic Resonance Spectroscopy of Fatty Acid Binding to Human Serum Albumin. Haeri HH, Tomaszewski J, Phytides B, Schimm H, Möslein G, Niedergethmann M, Hinderberger D, Gelos M. ACS Pharmacol Transl Sci 3 1188-1198 (2020)
  18. Interaction of Arylidenechromanone/Flavanone Derivatives with Biological Macromolecules Studied as Human Serum Albumin Binding, Cytotoxic Effect, Biocompatibility Towards Red Blood Cells. Adamus-Grabicka AA, Markowicz-Piasecka M, Ponczek MB, Kusz J, Małecka M, Krajewska U, Budzisz E. Molecules 23 E3172 (2018)
  19. Protein molecular surface mapped at different geometrical resolutions. Nicolau DV, Paszek E, Fulga F, Nicolau DV. PLoS One 8 e58896 (2013)
  20. Genetically encoded discovery of perfluoroaryl macrocycles that bind to albumin and exhibit extended circulation in vivo. Wong JYK, Ekanayake AI, Kharchenko S, Kirberger SE, Qiu R, Kelich P, Sarkar S, Li J, Fernandez KX, Alvizo-Paez ER, Miao J, Kalhor-Monfared S, John JD, Kang H, Choi H, Nuss JM, Vederas JC, Lin YS, Macauley MS, Vukovic L, Pomerantz WCK, Derda R. Nat Commun 14 5654 (2023)
  21. Mode of binding, kinetic and thermodynamic properties of a lipid-like drug (Fingolimod) interacting with Human Serum Albumin. Gholizadeh S, Haghaei H, Karami H, Soltani S, Zakariazadeh M, Shokri J. Bioimpacts 13 109-121 (2023)
  22. Probing the local conformational flexibility in receptor recognition: mechanistic insight from an atomic-scale investigation. Ding F, Peng W. RSC Adv 9 13968-13980 (2019)


Reviews citing this publication (66)

  1. The extraordinary ligand binding properties of human serum albumin. Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P, Notari S, Ascenzi P. IUBMB Life 57 787-796 (2005)
  2. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Kragh-Hansen U, Chuang VT, Otagiri M. Biol Pharm Bull 25 695-704 (2002)
  3. The thiol pool in human plasma: the central contribution of albumin to redox processes. Turell L, Radi R, Alvarez B. Free Radic Biol Med 65 244-253 (2013)
  4. Human serum albumin, systemic inflammation, and cirrhosis. Arroyo V, García-Martinez R, Salvatella X. J Hepatol 61 396-407 (2014)
  5. Understanding nucleic acid-ion interactions. Lipfert J, Doniach S, Das R, Herschlag D. Annu Rev Biochem 83 813-841 (2014)
  6. The Discovery and Development of Liraglutide and Semaglutide. Knudsen LB, Lau J. Front Endocrinol (Lausanne) 10 155 (2019)
  7. Hemoglobin and heme scavenging. Ascenzi P, Bocedi A, Visca P, Altruda F, Tolosano E, Beringhelli T, Fasano M. IUBMB Life 57 749-759 (2005)
  8. The proximal tubule and albuminuria: really! Dickson LE, Wagner MC, Sandoval RM, Molitoris BA. J Am Soc Nephrol 25 443-453 (2014)
  9. Review: Glycation of human serum albumin. Anguizola J, Matsuda R, Barnaby OS, Hoy KS, Wa C, DeBolt E, Koke M, Hage DS. Clin Chim Acta 425 64-76 (2013)
  10. Albumin-drug interaction and its clinical implication. Yamasaki K, Chuang VT, Chuang VT, Maruyama T, Otagiri M. Biochim Biophys Acta 1830 5435-5443 (2013)
  11. Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Curry S. Drug Metab Pharmacokinet 24 342-357 (2009)
  12. Ligand binding strategies of human serum albumin: how can the cargo be utilized? Varshney A, Sen P, Ahmad E, Rehan M, Subbarao N, Khan RH. Chirality 22 77-87 (2010)
  13. Strategies to extend plasma half-lives of recombinant antibodies. Kontermann RE. BioDrugs 23 93-109 (2009)
  14. Albumin and its application in drug delivery. Sleep D. Expert Opin Drug Deliv 12 793-812 (2015)
  15. In silico prediction of drug-binding strengths to human serum albumin. Colmenarejo G. Med Res Rev 23 275-301 (2003)
  16. Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT. Front Immunol 5 682 (2014)
  17. Interactive association of drugs binding to human serum albumin. Yang F, Zhang Y, Liang H. Int J Mol Sci 15 3580-3595 (2014)
  18. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Jannin B, Menzel M, Berlot JP, Delmas D, Lançon A, Latruffe N. Biochem Pharmacol 68 1113-1118 (2004)
  19. Polyunsaturated fatty acid modulation of voltage-gated ion channels. Boland LM, Drzewiecki MM. Cell Biochem Biophys 52 59-84 (2008)
  20. The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery. Bern M, Sand KM, Nilsen J, Sandlie I, Andersen JT. J Control Release 211 144-162 (2015)
  21. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Dasgupta A. Clin Chim Acta 377 1-13 (2007)
  22. Modeling kinetics of subcellular disposition of chemicals. Balaz S. Chem Rev 109 1793-1899 (2009)
  23. Stereoselective binding of human serum albumin. Chuang VT, Chuang VT, Otagiri M. Chirality 18 159-166 (2006)
  24. Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics. Zorzi A, Linciano S, Angelini A. Medchemcomm 10 1068-1081 (2019)
  25. Serum Albumin: A Multifaced Enzyme. De Simone G, di Masi A, Ascenzi P. Int J Mol Sci 22 10086 (2021)
  26. Beyond expansion: structural studies on the transport roles of human serum albumin. Curry S. Vox Sang 83 Suppl 1 315-319 (2002)
  27. Supramolecular exciton chirality of carotenoid aggregates. Simonyi M, Bikádi Z, Zsila F, Deli J. Chirality 15 680-698 (2003)
  28. Serum heme-albumin: an allosteric protein. Ascenzi P, Fasano M. IUBMB Life 61 1118-1122 (2009)
  29. Allosteric modulation of zinc speciation by fatty acids. Barnett JP, Blindauer CA, Kassaar O, Khazaipoul S, Martin EM, Sadler PJ, Stewart AJ. Biochim Biophys Acta 1830 5456-5464 (2013)
  30. A review of lipidation in the development of advanced protein and peptide therapeutics. Menacho-Melgar R, Decker JS, Hennigan JN, Lynch MD. J Control Release 295 1-12 (2019)
  31. Fatty acid binding to serum albumin: molecular simulation approaches. Fujiwara S, Amisaki T. Biochim Biophys Acta 1830 5427-5434 (2013)
  32. Oleanolic Acid: Extraction, Characterization and Biological Activity. Castellano JM, Ramos-Romero S, Perona JS. Nutrients 14 623 (2022)
  33. Sulfenic acid--a key intermediate in albumin thiol oxidation. Turell L, Botti H, Carballal S, Radi R, Alvarez B. J Chromatogr B Analyt Technol Biomed Life Sci 877 3384-3392 (2009)
  34. Role of membrane dynamics processes and exogenous molecules in cellular resveratrol uptake: consequences in bioavailability and activities. Delmas D, Lin HY. Mol Nutr Food Res 55 1142-1153 (2011)
  35. The oxido-redox potential of albumin methodological approach and relevance to human diseases. Candiano G, Petretto A, Bruschi M, Santucci L, Dimuccio V, Prunotto M, Gusmano R, Urbani A, Ghiggeri GM. J Proteomics 73 188-195 (2009)
  36. Serum albumin as a local therapeutic agent in cell therapy and tissue engineering. Horváthy DB, Simon M, Schwarz CM, Masteling M, Vácz G, Hornyák I, Lacza Z. Biofactors 43 315-330 (2017)
  37. Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics. Reddy LH, Bazile D. Adv Drug Deliv Rev 71 34-57 (2014)
  38. Heme-based catalytic properties of human serum albumin. Ascenzi P, di Masi A, Fanali G, Fasano M. Cell Death Discov 1 15025 (2015)
  39. Crosstalk between zinc and free fatty acids in plasma. Coverdale JPC, Khazaipoul S, Arya S, Stewart AJ, Blindauer CA. Biochim Biophys Acta Mol Cell Biol Lipids 1864 532-542 (2019)
  40. How fatty acids bind to proteins: the inside story from protein structures. Hamilton JA. Prostaglandins Leukot Essent Fatty Acids 67 65-72 (2002)
  41. Structural and Biochemical Features of Human Serum Albumin Essential for Eukaryotic Cell Culture. Mishra V, Heath RJ. Int J Mol Sci 22 8411 (2021)
  42. Albumin uptake and processing by the proximal tubule: physiological, pathological, and therapeutic implications. Molitoris BA, Sandoval RM, Yadav SPS, Wagner MC. Physiol Rev 102 1625-1667 (2022)
  43. Fatty acids as therapeutic auxiliaries for oral and parenteral formulations. Hackett MJ, Zaro JL, Shen WC, Guley PC, Cho MJ. Adv Drug Deliv Rev 65 1331-1339 (2013)
  44. Using bound fatty acids to disclose the functional structure of serum albumin. Reichenwallner J, Hinderberger D. Biochim Biophys Acta 1830 5382-5393 (2013)
  45. Ischemia-modified albumin: Crosstalk between fatty acid and cobalt binding. Coverdale JPC, Katundu KGH, Sobczak AIS, Arya S, Blindauer CA, Stewart AJ. Prostaglandins Leukot Essent Fatty Acids 135 147-157 (2018)
  46. Precision polymers--modern tools to understand and program macromolecular interactions. Börner HG. Macromol Rapid Commun 32 115-126 (2011)
  47. Protein-based nanotubes for biomedical applications. Komatsu T. Nanoscale 4 1910-1918 (2012)
  48. Seventy-Five Years of Research on Protein Binding. Dalhoff A. Antimicrob Agents Chemother 62 e01663-17 (2018)
  49. Studies of metabolite-protein interactions: a review. Matsuda R, Bi C, Anguizola J, Sobansky M, Rodriguez E, Vargas Badilla J, Zheng X, Hage B, Hage DS. J Chromatogr B Analyt Technol Biomed Life Sci 966 48-58 (2014)
  50. Human plasma lipocalins and serum albumin: Plasma alternative carriers? di Masi A, Trezza V, Leboffe L, Ascenzi P. J Control Release 228 191-205 (2016)
  51. Lessons on the critical interplay between zinc binding and protein structure and dynamics. Blindauer CA. J Inorg Biochem 121 145-155 (2013)
  52. Ischemia-Modified Albumin as a Marker of Acute Coronary Syndrome: The Case for Revising the Concept of "N-Terminal Modification" to "Fatty Acid Occupation" of Albumin. Oran I, Oran B. Dis Markers 2017 5692583 (2017)
  53. In silico prediction of human serum albumin binding for drug leads. Vallianatou T, Lambrinidis G, Tsantili-Kakoulidou A. Expert Opin Drug Discov 8 583-595 (2013)
  54. Intrinsically Disordered Regions in Serum Albumin: What Are They For? Litus EA, Permyakov SE, Uversky VN, Permyakov EA. Cell Biochem Biophys 76 39-57 (2018)
  55. The Interplay between Non-Esterified Fatty Acids and Plasma Zinc and Its Influence on Thrombotic Risk in Obesity and Type 2 Diabetes. Hierons SJ, Marsh JS, Wu D, Blindauer CA, Stewart AJ. Int J Mol Sci 22 10140 (2021)
  56. Using albumin to improve the therapeutic properties of diabetes treatments. Ahrén B, Burke B. Diabetes Obes Metab 14 121-129 (2012)
  57. Derivatization with fatty acids in peptide and protein drug discovery. Kurtzhals P, Østergaard S, Nishimura E, Kjeldsen T. Nat Rev Drug Discov 22 59-80 (2023)
  58. Strategies for Therapeutic Amelioration of Aberrant Plasma Zn2+ Handling in Thrombotic Disease: Targeting Fatty Acid/Serum Albumin-Mediated Effects. Regan-Smith S, Fritzen R, Hierons SJ, Ajjan RA, Blindauer CA, Stewart AJ. Int J Mol Sci 23 10302 (2022)
  59. [Derivative spectrophotometric and NMR spectroscopic study in pharmaceutical science]. Kitamura K. Yakugaku Zasshi 127 1621-1642 (2007)
  60. Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis. Bitto N, Ghigliazza G, Lavorato S, Caputo C, La Mura V. J Clin Med 12 934 (2023)
  61. Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis. Kugelmas M, Loftus M, Owen EJ, Wadei H, Saab S. Am J Health Syst Pharm 80 806-817 (2023)
  62. Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure. Saeidinejad M, Elshabrawi A, Sriphoosanaphan S, Andreola F, Mehta G, Agarwal B, Jalan R. Semin Liver Dis 43 429-445 (2023)
  63. Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy. Amatya R, Lee D, Min KA, Shin MC. Pharmaceutics 15 1963 (2023)
  64. The role of Zn2+ in shaping intracellular Ca2+ dynamics in the heart. Dorward AM, Stewart AJ, Pitt SJ. J Gen Physiol 155 e202213206 (2023)
  65. Unraveling the versatility of human serum albumin - A comprehensive review of its biological significance and therapeutic potential. Ashraf S, Qaiser H, Tariq S, Khalid A, Makeen HA, Alhazmi HA, Ul-Haq Z. Curr Res Struct Biol 6 100114 (2023)
  66. [Advances in chromatography in the study of drug-plasma protein interactions]. Bai Y, Fan Y, Ge G, Wang F. Se Pu 39 1077-1085 (2021)

Articles citing this publication (333)

  1. Structural basis of the drug-binding specificity of human serum albumin. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. J Mol Biol 353 38-52 (2005)
  2. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. Petitpas I, Grüne T, Bhattacharya AA, Curry S. J Mol Biol 314 955-960 (2001)
  3. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. Zunszain PA, Ghuman J, Komatsu T, Tsuchida E, Curry S. BMC Struct Biol 3 6 (2003)
  4. Predicting plasma protein binding of drugs: a new approach. Kratochwil NA, Huber W, Müller F, Kansy M, Gerber PR. Biochem Pharmacol 64 1355-1374 (2002)
  5. Structures of bovine, equine and leporine serum albumin. Bujacz A. Acta Crystallogr D Biol Crystallogr 68 1278-1289 (2012)
  6. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. Simard JR, Zunszain PA, Hamilton JA, Curry S. J Mol Biol 361 336-351 (2006)
  7. Probing three-dimensional structure of bovine serum albumin by chemical cross-linking and mass spectrometry. Huang BX, Kim HY, Dass C. J Am Soc Mass Spectrom 15 1237-1247 (2004)
  8. Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. Simard JR, Zunszain PA, Ha CE, Yang JS, Bhagavan NV, Petitpas I, Curry S, Hamilton JA. Proc Natl Acad Sci U S A 102 17958-17963 (2005)
  9. Probing the binding of the flavonoid, quercetin to human serum albumin by circular dichroism, electronic absorption spectroscopy and molecular modelling methods. Zsila F, Bikádi Z, Simonyi M. Biochem Pharmacol 65 447-456 (2003)
  10. Structural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemia. Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, Bhagavan NV, Curry S. Proc Natl Acad Sci U S A 100 6440-6445 (2003)
  11. Effects of Tween 20 and Tween 80 on the stability of Albutropin during agitation. Chou DK, Krishnamurthy R, Randolph TW, Carpenter JF, Manning MC. J Pharm Sci 94 1368-1381 (2005)
  12. Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. Zunszain PA, Ghuman J, McDonagh AF, Curry S. J Mol Biol 381 394-406 (2008)
  13. Identification and characterization of oxidized human serum albumin. A slight structural change impairs its ligand-binding and antioxidant functions. Kawakami A, Kubota K, Yamada N, Tagami U, Takehana K, Sonaka I, Suzuki E, Hirayama K. FEBS J 273 3346-3357 (2006)
  14. Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin. Yang F, Bian C, Zhu L, Zhao G, Huang Z, Huang M. J Struct Biol 157 348-355 (2007)
  15. Interaction of cromolyn sodium with human serum albumin: a fluorescence quenching study. Hu YJ, Liu Y, Pi ZB, Qu SS. Bioorg Med Chem 13 6609-6614 (2005)
  16. Synchrotron-based small-angle X-ray scattering of proteins in solution. Skou S, Gillilan RE, Ando N. Nat Protoc 9 1727-1739 (2014)
  17. Effect of ibuprofen and warfarin on the allosteric properties of haem-human serum albumin. A spectroscopic study. Baroni S, Mattu M, Vannini A, Cipollone R, Aime S, Ascenzi P, Fasano M. Eur J Biochem 268 6214-6220 (2001)
  18. Gold(III) complexes containing N-heterocyclic carbene ligands: thiol "switch-on" fluorescent probes and anti-cancer agents. Zou T, Lum CT, Chui SS, Che CM. Angew Chem Int Ed Engl 52 2930-2933 (2013)
  19. Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin. Lejon S, Frick IM, Björck L, Wikström M, Svensson S. J Biol Chem 279 42924-42928 (2004)
  20. Binding of fatty acids facilitates oxidation of cysteine-34 and converts copper-albumin complexes from antioxidants to prooxidants. Gryzunov YA, Arroyo A, Vigne JL, Zhao Q, Tyurin VA, Hubel CA, Gandley RE, Vladimirov YA, Taylor RN, Kagan VE. Arch Biochem Biophys 413 53-66 (2003)
  21. Fluorescence study on site-specific binding of perfluoroalkyl acids to human serum albumin. Chen YM, Guo LH. Arch Toxicol 83 255-261 (2009)
  22. A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography. Zhu L, Yang F, Chen L, Meehan EJ, Huang M. J Struct Biol 162 40-49 (2008)
  23. Polyfluoroalkyl chemicals in the serum and milk of breastfeeding women. von Ehrenstein OS, Fenton SE, Kato K, Kuklenyik Z, Calafat AM, Hines EP. Reprod Toxicol 27 239-245 (2009)
  24. Interactions of very long-chain saturated fatty acids with serum albumin. Choi JK, Ho J, Curry S, Qin D, Bittman R, Hamilton JA. J Lipid Res 43 1000-1010 (2002)
  25. Chain length-dependent binding of fatty acid anions to human serum albumin studied by site-directed mutagenesis. Kragh-Hansen U, Watanabe H, Nakajou K, Iwao Y, Otagiri M. J Mol Biol 363 702-712 (2006)
  26. Detergents as probes of hydrophobic binding cavities in serum albumin and other water-soluble proteins. Kragh-Hansen U, Hellec F, de Foresta B, le Maire M, Møller JV. Biophys J 80 2898-2911 (2001)
  27. Exploitation of the dual-emissive properties of cyclometalated iridium(III)-polypyridine complexes in the development of luminescent biological probes. Lo KK, Zhang KY, Leung SK, Tang MC. Angew Chem Int Ed Engl 47 2213-2216 (2008)
  28. How do fatty acids cause allosteric binding of drugs to human serum albumin? Chuang VT, Otagiri M. Pharm Res 19 1458-1464 (2002)
  29. Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin. Ryan AJ, Ghuman J, Zunszain PA, Chung CW, Curry S. J Struct Biol 174 84-91 (2011)
  30. The adherence of platelets to adsorbed albumin by receptor-mediated recognition of binding sites exposed by adsorption-induced unfolding. Sivaraman B, Latour RA. Biomaterials 31 1036-1044 (2010)
  31. Targeted non-covalent self-assembled nanoparticles based on human serum albumin. Bunschoten A, Buckle T, Kuil J, Luker GD, Luker KE, Nieweg OE, van Leeuwen FW. Biomaterials 33 867-875 (2012)
  32. Heme impairs allosterically drug binding to human serum albumin Sudlow's site I. Ascenzi P, Bocedi A, Notari S, Menegatti E, Fasano M. Biochem Biophys Res Commun 334 481-486 (2005)
  33. Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin. Sivertsen A, Isaksson J, Leiros HK, Svenson J, Svendsen JS, Brandsdal BO. BMC Struct Biol 14 4 (2014)
  34. Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin. Hein KL, Kragh-Hansen U, Morth JP, Jeppesen MD, Otzen D, Møller JV, Nissen P. J Struct Biol 171 353-360 (2010)
  35. Identification of high affinity fatty acid binding sites on human serum albumin by MM-PBSA method. Fujiwara S, Amisaki T. Biophys J 94 95-103 (2008)
  36. Stoichiometry and affinity of the human serum albumin-Alzheimer's Aβ peptide interactions. Milojevic J, Melacini G. Biophys J 100 183-192 (2011)
  37. Betulinic acid binding to human serum albumin: a study of protein conformation and binding affinity. Subramanyam R, Gollapudi A, Bonigala P, Chinnaboina M, Amooru DG. J Photochem Photobiol B 94 8-12 (2009)
  38. Molecular interaction studies of trimethoxy flavone with human serum albumin. Gokara M, Sudhamalla B, Amooru DG, Subramanyam R. PLoS One 5 e8834 (2010)
  39. Allosteric modulation of myristate and Mn(III)heme binding to human serum albumin. Optical and NMR spectroscopy characterization. Fanali G, Fesce R, Agrati C, Ascenzi P, Fasano M. FEBS J 272 4672-4683 (2005)
  40. Structural studies of bovine, equine, and leporine serum albumin complexes with naproxen. Bujacz A, Zielinski K, Sekula B. Proteins 82 2199-2208 (2014)
  41. Probing conformational changes of human serum albumin due to unsaturated fatty acid binding by chemical cross-linking and mass spectrometry. Huang BX, Dass C, Kim HY. Biochem J 387 695-702 (2005)
  42. Peptide mapping of human serum albumin modified minimally by methylglyoxal in vitro and in vivo. Ahmed N, Thornalley PJ. Ann N Y Acad Sci 1043 260-266 (2005)
  43. A spectroscopic study of the interaction of isoflavones with human serum albumin. Mahesha HG, Singh SA, Srinivasan N, Rao AG. FEBS J 273 451-467 (2006)
  44. A thermodynamic analysis of the binding interaction between polysorbate 20 and 80 with human serum albumins and immunoglobulins: a contribution to understand colloidal protein stabilisation. Garidel P, Hoffmann C, Blume A. Biophys Chem 143 70-78 (2009)
  45. Conformational study of human serum albumin in pre-denaturation temperatures by differential scanning calorimetry, circular dichroism and UV spectroscopy. Rezaei Tavirani M, Moghaddamnia SH, Ranjbar B, Amani M, Marashi SA. J Biochem Mol Biol 39 530-536 (2006)
  46. S-Nitrosylation of human variant albumin Liprizzi (R410C) confers potent antibacterial and cytoprotective properties. Ishima Y, Sawa T, Kragh-Hansen U, Miyamoto Y, Matsushita S, Akaike T, Otagiri M. J Pharmacol Exp Ther 320 969-977 (2007)
  47. Ratiometric analysis of fluorescence lifetime for probing binding sites in albumin with near-infrared fluorescent molecular probes. Berezin MY, Lee H, Akers W, Nikiforovich G, Achilefu S. Photochem Photobiol 83 1371-1378 (2007)
  48. Binding of a fluorescent lipid amphiphile to albumin and its transfer to lipid bilayer membranes. Abreu MS, Estronca LM, Moreno MJ, Vaz WL. Biophys J 84 386-399 (2003)
  49. Dewetting transitions in protein cavities. Young T, Hua L, Huang X, Abel R, Friesner R, Berne BJ. Proteins 78 1856-1869 (2010)
  50. Treatment of rat spinal cord injury with the neurotrophic factor albumin-oleic acid: translational application for paralysis, spasticity and pain. Avila-Martin G, Galan-Arriero I, Gómez-Soriano J, Taylor J. PLoS One 6 e26107 (2011)
  51. A molecular mechanism for modulating plasma Zn speciation by fatty acids. Lu J, Stewart AJ, Sleep D, Sadler PJ, Pinheiro TJ, Blindauer CA. J Am Chem Soc 134 1454-1457 (2012)
  52. Crystallographic studies of the complexes of bovine and equine serum albumin with 3,5-diiodosalicylic acid. Sekula B, Zielinski K, Bujacz A. Int J Biol Macromol 60 316-324 (2013)
  53. Determining the molecular interactions of perfluorinated carboxylic acids with human sera and isolated human serum albumin using nuclear magnetic resonance spectroscopy. D'eon JC, Simpson AJ, Kumar R, Baer AJ, Mabury SA. Environ Toxicol Chem 29 1678-1688 (2010)
  54. Characterization of interaction property of multicomponents in Chinese Herb with protein by microdialysis combined with HPLC. Guo M, Su X, Kong L, Li X, Zou H. Anal Chim Acta 556 183-188 (2006)
  55. Fluorometric investigation of the interaction between methylene blue and human serum albumin. Hu YJ, Li W, Liu Y, Dong JX, Qu SS. J Pharm Biomed Anal 39 740-745 (2005)
  56. Ibuprofen impairs allosterically peroxynitrite isomerization by ferric human serum heme-albumin. Ascenzi P, di Masi A, Coletta M, Ciaccio C, Fanali G, Nicoletti FP, Smulevich G, Fasano M. J Biol Chem 284 31006-31017 (2009)
  57. Surface chemistry-mediated modulation of adsorbed albumin folding state specifies nanocarrier clearance by distinct macrophage subsets. Vincent MP, Bobbala S, Karabin NB, Frey M, Liu Y, Navidzadeh JO, Stack T, Scott EA. Nat Commun 12 648 (2021)
  58. Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin. Bocedi A, Notari S, Menegatti E, Fanali G, Fasano M, Ascenzi P. FEBS J 272 6287-6296 (2005)
  59. Binding constant determination of drugs toward subdomain IIIA of human serum albumin by near-infrared dye-displacement capillary electrophoresis. Sowell J, Mason JC, Strekowski L, Patonay G. Electrophoresis 22 2512-2517 (2001)
  60. Interaction of perfluorooctanoic acid with human serum albumin. Wu LL, Gao HW, Gao NY, Chen FF, Chen L. BMC Struct Biol 9 31 (2009)
  61. Multiple binding modes of ibuprofen in human serum albumin identified by absolute binding free energy calculations. Evoli S, Mobley DL, Guzzi R, Rizzuti B. Phys Chem Chem Phys 18 32358-32368 (2016)
  62. A molecular dynamics study of human serum albumin binding sites. Artali R, Bombieri G, Calabi L, Del Pra A. Farmaco 60 485-495 (2005)
  63. Elucidation of the binding mechanism of coumarin derivatives with human serum albumin. Garg A, Manidhar DM, Gokara M, Malleda C, Suresh Reddy C, Subramanyam R. PLoS One 8 e63805 (2013)
  64. Plasma free fatty acid levels influence Zn(2+) -dependent histidine-rich glycoprotein-heparin interactions via an allosteric switch on serum albumin. Kassaar O, Schwarz-Linek U, Blindauer CA, Stewart AJ. J Thromb Haemost 13 101-110 (2015)
  65. A protein-supported fluorescent reagent for the highly-sensitive and selective detection of mercury ions in aqueous solution and live cells. Ma LJ, Li Y, Li L, Sun J, Tian C, Wu Y. Chem Commun (Camb) 6345-6347 (2008)
  66. Binding of erucic acid with human serum albumin using a spectroscopic and molecular docking study. Rabbani G, Baig MH, Jan AT, Ju Lee E, Khan MV, Zaman M, Farouk AE, Khan RH, Choi I. Int J Biol Macromol 105 1572-1580 (2017)
  67. DEER in biological multispin-systems: a case study on the fatty acid binding to human serum albumin. Junk MJ, Spiess HW, Hinderberger D. J Magn Reson 210 210-217 (2011)
  68. Ibuprofen binding to secondary sites allosterically modulates the spectroscopic and catalytic properties of human serum heme-albumin. di Masi A, Gullotta F, Bolli A, Fanali G, Fasano M, Ascenzi P. FEBS J 278 654-662 (2011)
  69. Modulation of heme and myristate binding to human serum albumin by anti-HIV drugs. An optical and NMR spectroscopic study. Fanali G, Bocedi A, Ascenzi P, Fasano M. FEBS J 274 4491-4502 (2007)
  70. Interaction of human serum albumin with short polyelectrolytes: a study by calorimetry and computer simulations. Yu S, Xu X, Yigit C, van der Giet M, Zidek W, Jankowski J, Dzubiella J, Ballauff M. Soft Matter 11 4630-4639 (2015)
  71. Protein phosphatase type 2Calpha and 2Cbeta are involved in fatty acid-induced apoptosis of neuronal and endothelial cells. Schwarz S, Hufnagel B, Dworak M, Klumpp S, Krieglstein J. Apoptosis 11 1111-1119 (2006)
  72. Screening and characterisation of antimicrobial properties of semisynthetic betulin derivatives. Haque S, Nawrot DA, Alakurtti S, Ghemtio L, Yli-Kauhaluoma J, Tammela P. PLoS One 9 e102696 (2014)
  73. Site-specific fatty acid-conjugation to prolong protein half-life in vivo. Lim SI, Mizuta Y, Takasu A, Hahn YS, Kim YH, Kwon I. J Control Release 170 219-225 (2013)
  74. Stopped-flow kinetic analysis of long-chain fatty acid dissociation from bovine serum albumin. Demant EJ, Richieri GV, Kleinfeld AM. Biochem J 363 809-815 (2002)
  75. About the albumin structure in solution: cigar Expanded form versus heart Normal shape. Leggio C, Galantini L, Pavel NV. Phys Chem Chem Phys 10 6741-6750 (2008)
  76. Binding of Thermomyces (Humicola) lanuginosa lipase to the mixed micelles of cis-parinaric acid/NaTDC. Yapoudjian S, Ivanova MG, Brzozowski AM, Patkar SA, Vind J, Svendsen A, Verger R. Eur J Biochem 269 1613-1621 (2002)
  77. Interactions of human serum albumin with retinoic acid, retinal and retinyl acetate. Karnaukhova E. Biochem Pharmacol 73 901-910 (2007)
  78. Mapping the interactions between the Alzheimer's Aβ-peptide and human serum albumin beyond domain resolution. Algamal M, Milojevic J, Jafari N, Zhang W, Melacini G. Biophys J 105 1700-1709 (2013)
  79. Novel binding studies of human serum albumin with trans-feruloyl maslinic acid. Subramanyam R, Goud M, Sudhamalla B, Reddeem E, Gollapudi A, Nellaepalli S, Yadavalli V, Chinnaboina M, Amooru DG. J Photochem Photobiol B 95 81-88 (2009)
  80. Surface-enhanced Raman spectroscopy study of the interaction of the antitumoral drug emodin with human serum albumin. Fabriciova G, Sanchez-Cortes S, Garcia-Ramos JV, Miskovsky P. Biopolymers 74 125-130 (2004)
  81. Updates on contemporary protein binding techniques. Chuang VT, Maruyama T, Otagiri M. Drug Metab Pharmacokinet 24 358-364 (2009)
  82. Molecular dynamics simulation studies of betulinic acid with human serum albumin. Malleda C, Ahalawat N, Gokara M, Subramanyam R. J Mol Model 18 2589-2597 (2012)
  83. Testosterone meets albumin - the molecular mechanism of sex hormone transport by serum albumins. Czub MP, Venkataramany BS, Majorek KA, Handing KB, Porebski PJ, Beeram SR, Suh K, Woolfork AG, Hage DS, Shabalin IG, Minor W. Chem Sci 10 1607-1618 (2019)
  84. A structure-based model for predicting serum albumin binding. Lexa KW, Dolghih E, Jacobson MP. PLoS One 9 e93323 (2014)
  85. Ibuprofen modulates allosterically NO dissociation from ferrous nitrosylated human serum heme-albumin by binding to three sites. Ascenzi P, di Masi A, De Sanctis G, Coletta M, Fasano M. Biochem Biophys Res Commun 387 83-86 (2009)
  86. Potential protein toxicity of synthetic pigments: binding of poncean S to human serum albumin. Gao HW, Xu Q, Chen L, Wang SL, Wang Y, Wu LL, Yuan Y. Biophys J 94 906-917 (2008)
  87. Structural basis of transport of lysophospholipids by human serum albumin. Guo S, Shi X, Yang F, Chen L, Meehan EJ, Bian C, Huang M. Biochem J 423 23-30 (2009)
  88. The distribution of fatty acids reveals the functional structure of human serum albumin. Junk MJ, Spiess HW, Hinderberger D. Angew Chem Int Ed Engl 49 8755-8759 (2010)
  89. Unraveling the binding mechanism of asiatic acid with human serum albumin and its biological implications. Gokara M, Malavath T, Kalangi SK, Reddana P, Subramanyam R. J Biomol Struct Dyn 32 1290-1302 (2014)
  90. Analysis of binding interaction between antibacterial ciprofloxacin and human serum albumin by spectroscopic techniques. Varshney A, Ansari Y, Zaidi N, Ahmad E, Badr G, Alam P, Khan RH. Cell Biochem Biophys 70 93-101 (2014)
  91. Binding of δ9-tetrahydrocannabinol and diazepam to human serum albumin. Fanali G, Cao Y, Ascenzi P, Trezza V, Rubino T, Parolaro D, Fasano M. IUBMB Life 63 446-451 (2011)
  92. Interaction of colchicine with human serum albumin investigated by spectroscopic methods. Hu YJ, Liu Y, Zhao RM, Qu SS. Int J Biol Macromol 37 122-126 (2005)
  93. Isoniazid and rifampicin inhibit allosterically heme binding to albumin and peroxynitrite isomerization by heme-albumin. Ascenzi P, Bolli A, di Masi A, Tundo GR, Fanali G, Coletta M, Fasano M. J Biol Inorg Chem 16 97-108 (2011)
  94. Serum albumin hydrogels in broad pH and temperature ranges: characterization of their self-assembled structures and nanoscopic and macroscopic properties. Arabi SH, Aghelnejad B, Schwieger C, Meister A, Kerth A, Hinderberger D. Biomater Sci 6 478-492 (2018)
  95. Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability. Kurono M, Fujii A, Murata M, Fujitani B, Negoro T. Biochem Pharmacol 71 338-353 (2006)
  96. Study of interactions between oppositely charged dendrigraft poly-L-lysine and human serum albumin by continuous frontal analysis capillary electrophoresis and fluorescence spectroscopy. Sisavath N, Leclercq L, Le Saux T, Oukacine F, Cottet H. J Chromatogr A 1289 127-132 (2013)
  97. Bovine serum albumin enhances nicotinic acetylcholine receptor function in mouse thalamic synaptosomes. Butt CM, Hutton SR, Marks MJ, Collins AC. J Neurochem 83 48-56 (2002)
  98. Drug-drug plasma protein binding interactions of ivacaftor. Schneider EK, Huang JX, Carbone V, Baker M, Azad MA, Cooper MA, Li J, Velkov T. J Mol Recognit 28 339-348 (2015)
  99. Steric and allosteric effects of fatty acids on the binding of warfarin to human serum albumin revealed by molecular dynamics and free energy calculations. Fujiwara S, Amisaki T. Chem Pharm Bull (Tokyo) 59 860-867 (2011)
  100. Structural basis for the binding of naproxen to human serum albumin in the presence of fatty acids and the GA module. Lejon S, Cramer JF, Nordberg P. Acta Crystallogr Sect F Struct Biol Cryst Commun 64 64-69 (2008)
  101. Structural basis of non-steroidal anti-inflammatory drug diclofenac binding to human serum albumin. Zhang Y, Lee P, Liang S, Zhou Z, Wu X, Yang F, Liang H. Chem Biol Drug Des 86 1178-1184 (2015)
  102. Three-dimensional structure/function analysis of SCP-2-like2 reveals differences among SCP-2 family members. Dyer DH, Wessely V, Forest KT, Lan Q. J Lipid Res 49 644-653 (2008)
  103. Allosteric modulation of monomeric proteins*. Ascenzi P, Bocedi A, Bolli A, Fasano M, Notari S, Polticelli F. Biochem Mol Biol Educ 33 169-176 (2005)
  104. Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation. Li J, Zhu X, Yang C, Shi R. J Mol Model 16 789-798 (2010)
  105. Effects of Fatty Acids and Glycation on Drug Interactions with Human Serum Albumin. Anguizola JA, Basiaga SB, Hage DS. Curr Metabolomics 1 239-250 (2013)
  106. In vitro pyrogen test for toxic or immunomodulatory drugs. Daneshian M, Guenther A, Wendel A, Hartung T, von Aulock S. J Immunol Methods 313 169-175 (2006)
  107. Neutrophil-mediated oxidative stress and albumin structural damage predict COVID-19-associated mortality. Badawy MA, Yasseen BA, El-Messiery RM, Abdel-Rahman EA, Elkhodiry AA, Kamel AG, El-Sayed H, Shedra AM, Hamdy R, Zidan M, Al-Raawi D, Hammad M, Elsharkawy N, El Ansary M, Al-Halfawy A, Elhadad A, Hatem A, Abouelnaga S, Dugan LL, Ali SS. Elife 10 e69417 (2021)
  108. Strategy for Extending Half-life in Drug Design and Its Significance. Gunaydin H, Altman MD, Ellis JM, Fuller P, Johnson SA, Lahue B, Lapointe B. ACS Med Chem Lett 9 528-533 (2018)
  109. α-Tocopherol binding to human serum albumin. Fanali G, Fasano M, Ascenzi P, Zingg JM, Azzi A. Biofactors 39 294-303 (2013)
  110. Elephant albumin: a multipurpose pheromone shuttle. Lazar J, Lazar J, Rasmussen LE, Greenwood DR, Bang IS, Prestwich GD. Chem Biol 11 1093-1100 (2004)
  111. Fatty acids binding to human serum albumin: Changes of reactivity and glycation level of Cysteine-34 free thiol group with methylglyoxal. Pavićević ID, Jovanović VB, Takić MM, Penezić AZ, Aćimović JM, Mandić LM. Chem Biol Interact 224 42-50 (2014)
  112. Plasma fatty acid levels may regulate the Zn(2+)-dependent activities of histidine-rich glycoprotein. Stewart AJ, Blindauer CA, Sadler PJ. Biochimie 91 1518-1522 (2009)
  113. Reductive nitrosylation of ferric human serum heme-albumin. Ascenzi P, Cao Y, di Masi A, Gullotta F, De Sanctis G, Fanali G, Fasano M, Coletta M. FEBS J 277 2474-2485 (2010)
  114. The Use of Human, Bovine, and Camel Milk Albumins in Anticancer Complexes with Oleic Acid. El-Fakharany EM, Abu-Serie MM, Litus EA, Permyakov SE, Permyakov EA, Uversky VN, Redwan EM. Protein J 37 203-215 (2018)
  115. Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides. Li Y, Wang Y, Wei Q, Zheng X, Tang L, Kong D, Gong M. Sci Rep 5 18039 (2015)
  116. 19F NMR spectroscopic study on the binding of triflupromazine to bovine and human serum albumins. Kitamura K, Kume M, Yamamoto M, Takegami S, Kitade T. J Pharm Biomed Anal 36 411-414 (2004)
  117. Binding properties of hydrophobic molecules to human serum albumin studied by fluorescence titration. Takehara K, Yuki K, Shirasawa M, Yamasaki S, Yamada S. Anal Sci 25 115-120 (2009)
  118. Cigarette smoke induces p-benzoquinone-albumin adduct in blood serum: Implications on structure and ligand binding properties. Ghosh A, Choudhury A, Das A, Chatterjee NS, Das T, Chowdhury R, Panda K, Banerjee R, Chatterjee IB. Toxicology 292 78-89 (2012)
  119. Histidine146 of human serum albumin plays a prominent role at the interface of subdomains IA and IIA in allosteric ligand binding. Kaneko K, Chuang VT, Chuang VT, Minomo A, Yamasaki K, Bhagavan NV, Maruyama T, Otagiri M. IUBMB Life 63 277-285 (2011)
  120. NMR metabolomics profiling of blood plasma mimics shows that medium- and long-chain fatty acids differently release metabolites from human serum albumin. Jupin M, Michiels PJ, Girard FC, Spraul M, Wijmenga SS. J Magn Reson 239 34-43 (2014)
  121. NMR reveals molecular interactions and dynamics of fatty acid binding to albumin. Hamilton JA. Biochim Biophys Acta 1830 5418-5426 (2013)
  122. Fatty acid binding into the highest affinity site of human serum albumin observed in molecular dynamics simulation. Rizzuti B, Bartucci R, Sportelli L, Guzzi R. Arch Biochem Biophys 579 18-25 (2015)
  123. Imatinib binding to human serum albumin modulates heme association and reactivity. Di Muzio E, Polticelli F, Trezza V, Fanali G, Fasano M, Ascenzi P. Arch Biochem Biophys 560 100-112 (2014)
  124. Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albumin. Yamasaki K, Hyodo S, Taguchi K, Nishi K, Yamaotsu N, Hirono S, Chuang VTG, Seo H, Maruyama T, Otagiri M. PLoS One 12 e0180404 (2017)
  125. NMR identification of endogenous metabolites interacting with fatted and non-fatted human serum albumin in blood plasma: Fatty acids influence the HSA-metabolite interaction. Jupin M, Michiels PJ, Girard FC, Spraul M, Wijmenga SS. J Magn Reson 228 81-94 (2013)
  126. Tyrosine fluorescence probing of the surfactant-induced conformational changes of albumin. Zhdanova NG, Shirshin EA, Maksimov EG, Panchishin IM, Saletsky AM, Fadeev VV. Photochem Photobiol Sci 14 897-908 (2015)
  127. A polyphenylene dendrimer drug transporter with precisely positioned amphiphilic surface patches. Stangenberg R, Wu Y, Hedrich J, Kurzbach D, Wehner D, Weidinger G, Kuan SL, Jansen MI, Jelezko F, Luhmann HJ, Hinderberger D, Weil T, Müllen K. Adv Healthc Mater 4 377-384 (2015)
  128. Affinity and specificity of levamlodipine-human serum albumin interactions: insights into its carrier function. Liu Z, Zheng X, Yang X, Wang E, Wang J. Biophys J 96 3917-3925 (2009)
  129. Caprylate as the albumin-selective modifier to improve IgG purification with hydrophobic charge-induction chromatography. Tong HF, Lin DQ, Gao D, Yuan XM, Yao SJ. J Chromatogr A 1285 88-96 (2013)
  130. Experimental and computational surface hydrophobicity analysis of a non-enveloped virus and proteins. Heldt CL, Zahid A, Vijayaragavan KS, Mi X. Colloids Surf B Biointerfaces 153 77-84 (2017)
  131. Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment. Giacobbe DR, di Masi A, Leboffe L, Del Bono V, Rossi M, Cappiello D, Coppo E, Marchese A, Casulli A, Signori A, Novelli A, Perrone K, Principe L, Bandera A, Vender LE, Misin A, Occhilupo P, Melone M, Ascenzi P, Gori A, Luzzati R, Viscoli C, Di Bella S. Sci Rep 8 11968 (2018)
  132. Isolation of esterified fatty acids bound to serum albumin purified from human plasma and characterised by MALDI mass spectrometry. Belgacem O, Stübiger G, Allmaier G, Buchacher A, Pock K. Biologicals 35 43-49 (2007)
  133. Mechanism of binding of warfarin enantiomers to recombinant domains of human albumin. Twine SM, Gore MG, Morton P, Fish BC, Lee AG, East JM. Arch Biochem Biophys 414 83-90 (2003)
  134. Molecular modeling and functional confirmation of a predicted fatty acid binding site of mitochondrial aspartate aminotransferase. Bradbury MW, Stump D, Guarnieri F, Berk PD. J Mol Biol 412 412-422 (2011)
  135. The five-to-six-coordination transition of ferric human serum heme-albumin is allosterically-modulated by ibuprofen and warfarin: a combined XAS and MD study. Meneghini C, Leboffe L, Bionducci M, Fanali G, Meli M, Colombo G, Fasano M, Ascenzi P, Mobilio S. PLoS One 9 e104231 (2014)
  136. Warfarin modulates the nitrite reductase activity of ferrous human serum heme-albumin. Ascenzi P, Tundo GR, Fanali G, Coletta M, Fasano M. J Biol Inorg Chem 18 939-946 (2013)
  137. A novel approach for measuring sphingosine-1-phosphate and lysophosphatidic acid binding to carrier proteins using monoclonal antibodies and the Kinetic Exclusion Assay. Fleming JK, Glass TR, Lackie SJ, Wojciak JM. J Lipid Res 57 1737-1747 (2016)
  138. Differential interactions and structural stability of chitosan oligomers with human serum albumin and α-1-glycoprotein. Gokara M, Kimavath GB, Podile AR, Subramanyam R. J Biomol Struct Dyn 33 196-210 (2015)
  139. Energetics of the interactions of human serum albumin with cationic surfactant. Bordbar AK, Taheri-Kafrani A, Mousavi SH, Haertlé T. Arch Biochem Biophys 470 103-110 (2008)
  140. Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation. Cho J, Lim SI, Yang BS, Hahn YS, Kwon I. Sci Rep 7 18041 (2017)
  141. Human Serum Albumin Increases the Stability of Green Tea Catechins in Aqueous Physiological Conditions. Zinellu A, Sotgia S, Scanu B, Forteschi M, Giordo R, Cossu A, Posadino AM, Carru C, Pintus G. PLoS One 10 e0134690 (2015)
  142. Sequence analysis of serum albumins reveals the molecular evolution of ligand recognition properties. Fanali G, Ascenzi P, Bernardi G, Fasano M. J Biomol Struct Dyn 29 691-701 (2012)
  143. Strength training attenuates post-infarct cardiac dysfunction and remodeling. Garza MA, Wason EA, Cruger JR, Chung E, Zhang JQ. J Physiol Sci 69 523-530 (2019)
  144. Subdomain IIIA of dog albumin contains a binding site similar to site II of human albumin. Kaneko K, Fukuda H, Chuang VT, Yamasaki K, Kawahara K, Nakayama H, Suenaga A, Maruyama T, Otagiri M. Drug Metab Dispos 36 81-86 (2008)
  145. Characterizing Active Pharmaceutical Ingredient Binding to Human Serum Albumin by Spin-Labeling and EPR Spectroscopy. Hauenschild T, Reichenwallner J, Enkelmann V, Hinderberger D. Chemistry 22 12825-12838 (2016)
  146. Identification and Characterization of a Single High-Affinity Fatty Acid Binding Site in Human Serum Albumin. Wenskowsky L, Schreuder H, Derdau V, Matter H, Volkmar J, Nazaré M, Opatz T, Petry S. Angew Chem Int Ed Engl 57 1044-1048 (2018)
  147. In vitro binding of leukotriene B4 (LTB4) to human serum albumin: evidence from spectroscopic, molecular modeling, and competitive displacement studies. Zsila F, Bikádi Z, Lockwood SF. Bioorg Med Chem Lett 15 3725-3731 (2005)
  148. Kinetics of fatty acid binding ability of glycated human serum albumin. Yamazaki E, Inagaki M, Kurita O, Inoue T. J Biosci 30 475-481 (2005)
  149. Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. Shabto JM, Martini DJ, Liu Y, Ravindranathan D, Brown J, Hitron EE, Russler GA, Caulfield S, Kissick H, Alemozaffar M, Ogan K, Harris WB, Master VA, Kucuk O, Carthon BC, Bilen MA. Cancer Med 9 2752-2760 (2020)
  150. Real-time partitioning of octadecyl rhodamine B into bead-supported lipid bilayer membranes revealing quantitative differences in saturable binding sites in DOPC and 1:1:1 DOPC/SM/cholesterol membranes. Buranda T, Wu Y, Perez D, Chigaev A, Sklar LA. J Phys Chem B 114 1336-1349 (2010)
  151. Reciprocal allosteric modulation of carbon monoxide and warfarin binding to ferrous human serum heme-albumin. Bocedi A, De Sanctis G, Ciaccio C, Tundo GR, Di Masi A, Fanali G, Nicoletti FP, Fasano M, Smulevich G, Ascenzi P, Coletta M. PLoS One 8 e58842 (2013)
  152. Titanocene anticancer complexes and their binding mode of action to human serum albumin: a computational study. Sarsam SW, Nutt DR, Strohfeldt K, Watson KA. Metallomics 3 152-161 (2011)
  153. A model mechanism for protein precipitation by caprylic acid: application to plasma purification. Morais V, Massaldi H. Biotechnol Appl Biochem 59 50-54 (2012)
  154. All-trans-retinoic acid and retinol binding to the FA1 site of human serum albumin competitively inhibits heme-Fe(III) association. Di Muzio E, Polticelli F, di Masi A, Fanali G, Fasano M, Ascenzi P. Arch Biochem Biophys 590 56-63 (2016)
  155. Binding of anti-Parkinson's disease drugs to human serum albumin is allosterically modulated. Fanali G, Rampoldi V, di Masi A, Bolli A, Lopiano L, Ascenzi P, Fasano M. IUBMB Life 62 371-376 (2010)
  156. Comparative studies of unfolding and binding of ligands to human serum albumin in the presence of fatty acid: spectroscopic approach. Varshney A, Ahmad B, Khan RH. Int J Biol Macromol 42 483-490 (2008)
  157. Crystal structure of equine serum albumin in complex with cetirizine reveals a novel drug binding site. Handing KB, Shabalin IG, Szlachta K, Majorek KA, Minor W. Mol Immunol 71 143-151 (2016)
  158. Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals. Basken NE, Mathias CJ, Green MA. J Pharm Sci 98 2170-2179 (2009)
  159. Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide. Gajahi Soudahome A, Catan A, Giraud P, Assouan Kouao S, Guerin-Dubourg A, Debussche X, Le Moullec N, Bourdon E, Bravo SB, Paradela-Dobarro B, Álvarez E, Meilhac O, Rondeau P, Couprie J. J Biol Chem 293 4778-4791 (2018)
  160. Human serum albumin-based design of a diflunisal prodrug. Yang F, Ma ZY, Zhang Y, Li GQ, Li M, Qin JK, Lockridge O, Liang H. Eur J Pharm Biopharm 84 549-554 (2013)
  161. In situ spectroscopic quantification of protein-ice interactions. Twomey A, Less R, Kurata K, Takamatsu H, Aksan A. J Phys Chem B 117 7889-7897 (2013)
  162. Editorial Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity. Knudsen LB. ACS Pharmacol Transl Sci 2 468-484 (2019)
  163. Synthesis and structure of [(η(6)-p-cymene)Ru(2-anthracen-9-ylmethylene-N-ethylhydrazinecarbothioamide)Cl]Cl; biological evaluation, topoisomerase II inhibition and reaction with DNA and human serum albumin. Beckford F, Thessing J, Woods J, Didion J, Gerasimchuk N, Gonzalez-Sarrias A, Seeram NP. Metallomics 3 491-502 (2011)
  164. The influence of fatty acids on determination of human serum albumin thiol group. Jovanović VB, Pavićević ID, Takić MM, Penezić-Romanjuk AZ, Aćimović JM, Mandić LM. Anal Biochem 448 50-57 (2014)
  165. Visualizing ensembles in structural biology. Melvin RL, Salsbury FR. J Mol Graph Model 67 44-53 (2016)
  166. A Spectroscopic Approach to Investigate the Molecular Interactions between the Newly Approved Irreversible ErbB blocker "Afatinib" and Bovine Serum Albumin. Alanazi AM, Abdelhameed AS. PLoS One 11 e0146297 (2016)
  167. A fluorescent fatty acid probe, DAUDA, selectively displaces two myristates bound in human serum albumin. Wang Y, Luo Z, Shi X, Wang H, Nie L, Huang M. Protein Sci 20 2095-2101 (2011)
  168. A principal component analysis of the dynamics of subdomains and binding sites in human serum albumin. Paris G, Ramseyer C, Enescu M. Biopolymers 101 561-572 (2014)
  169. Albumin-mediated alteration of plasma zinc speciation by fatty acids modulates blood clotting in type-2 diabetes. Sobczak AIS, Katundu KGH, Phoenix FA, Khazaipoul S, Yu R, Lampiao F, Stefanowicz F, Blindauer CA, Pitt SJ, Smith TK, Ajjan RA, Stewart AJ. Chem Sci 12 4079-4093 (2021)
  170. Determining molecular binding sites on human serum albumin by displacement of oleic acid. Sarver RW, Gao H, Tian F. Anal Biochem 347 297-302 (2005)
  171. Gadofosveset-based biomarker of tissue albumin concentration: Technical validation in vitro and feasibility in vivo. Richardson OC, Bane O, Scott ML, Tanner SF, Waterton JC, Sourbron SP, Carroll TJ, Buckley DL. Magn Reson Med 73 244-253 (2015)
  172. Identification of saturated and unsaturated fatty acids released during microsomal incubations. Bushee JL, Liang G, Dunne CE, Harriman SP, Argikar UA. Xenobiotica 44 687-695 (2014)
  173. In Vitro Investigations of Acetohexamide Binding to Glycated Serum Albumin in the Presence of Fatty Acid. Szkudlarek A, Wilk M, Maciążek-Jurczyk M. Molecules 25 E2340 (2020)
  174. Maleimido-proxyl as an EPR spin label for the evaluation of conformational changes of albumin. Pavićević A, Luo J, Popović-Bijelić A, Mojović M. Eur Biophys J 46 773-787 (2017)
  175. Structural analysis and fatty acid-binding properties of two Croatian variants of human serum albumin. Kragh-Hansen U, Campagnoli M, Dodig S, Nielsen H, Benko B, Raos M, Cesati R, Sala A, Galliano M, Minchiotti L. Clin Chim Acta 349 105-112 (2004)
  176. The fate of anticancer drug, ellipticine in DPPC and DMPC liposomes upon interaction with HSA: a photophysical approach. Thakur R, Das A, Chakraborty A. J Photochem Photobiol B 130 122-131 (2014)
  177. The induction of apoptosis in pre-malignant keratinocytes by omega-3 polyunsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) is inhibited by albumin. Nikolakopoulou Z, Shaikh MH, Dehlawi H, Michael-Titus AT, Parkinson EK. Toxicol Lett 218 150-158 (2013)
  178. A femtosecond study of the interaction of human serum albumin with a surfactant (SDS). Mandal U, Ghosh S, Mitra G, Adhikari A, Dey S, Bhattacharyya K. Chem Asian J 3 1430-1434 (2008)
  179. Albuminoid genes: evolving at the interface of dispensability and selection. Mozzi A, Forni D, Cagliani R, Pozzoli U, Vertemara J, Bresolin N, Sironi M. Genome Biol Evol 6 2983-2997 (2014)
  180. Analysis of the Binding of Aripiprazole to Human Serum Albumin: The Importance of a Chloro-Group in the Chemical Structure. Sakurama K, Kawai A, Tuan Giam Chuang V, Kanamori Y, Osa M, Taguchi K, Seo H, Maruyama T, Imoto S, Yamasaki K, Otagiri M. ACS Omega 3 13790-13797 (2018)
  181. Binding of enterolactone and enterodiol to human serum albumin: increase of cysteine-34 thiol group reactivity. Takić MM, Jovanović VB, Pavićević ID, Uzelac TN, Aćimović JM, Ristić-Medić DK, Mandić LM. Food Funct 7 1217-1226 (2016)
  182. Biological and Physico-Chemical Characteristics of Arginine-Rich Peptide Gemini Surfactants with Lysine and Cystine Spacers. Neubauer D, Jaśkiewicz M, Bauer M, Olejniczak-Kęder A, Sikorska E, Sikora K, Kamysz W. Int J Mol Sci 22 3299 (2021)
  183. Chromatographic analysis of the effects of fatty acids and glycation on binding by probes for Sudlow sites I and II to human serum albumin. Anguizola J, Debolt E, Suresh D, Hage DS. J Chromatogr B Analyt Technol Biomed Life Sci 1021 175-181 (2016)
  184. Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats. Ogata K, Takamura N, Tokunaga J, Kawai K, Arimori K, Higuchi S. J Pharm Pharmacol 60 15-20 (2008)
  185. Effect of UVC radiation on conformational restructuring of human serum albumin. Michnik A, Michalik K, Drzazga Z. J Photochem Photobiol B 90 170-178 (2008)
  186. Fatty Acid Binding to Human Serum Albumin in Blood Serum Characterized by EPR Spectroscopy. Haeri HH, Schunk B, Tomaszewski J, Schimm H, Gelos MJ, Hinderberger D. ChemistryOpen 8 650-656 (2019)
  187. Fatty Acids Compete with Aβ in Binding to Serum Albumin by Quenching Its Conformational Flexibility. Guo C, Zhou HX. Biophys J 116 248-257 (2019)
  188. Fatty acid binding sites of human and bovine albumins: differences observed by spin probe ESR. Muravsky V, Gurachevskaya T, Berezenko S, Schnurr K, Gurachevsky A. Spectrochim Acta A Mol Biomol Spectrosc 74 42-47 (2009)
  189. Fetal bovine serum albumin inhibits antimicrobial peptide activity and binds drug only in complex with α1-antitrypsin. Tang WH, Wang CF, Liao YD. Sci Rep 11 1267 (2021)
  190. GC-FID determination and pharmacokinetic studies of oleanolic acid in human serum. Rada M, Castellano JM, Perona JS, Guinda Á. Biomed Chromatogr 29 1687-1692 (2015)
  191. Protein assisted fluorescence enhancement of a dansyl containing fluorescent reagent: detection of Hg+ ion in aqueous medium. Srivastava P, Shahid M, Misra A. Org Biomol Chem 9 5051-5055 (2011)
  192. Regulation of amantadine hydrochloride binding with IIA subdomain of human serum albumin by fatty acid chains. Yang F, Lee P, Ma Z, Ma L, Yang G, Wu X, Liang H. J Pharm Sci 102 84-92 (2013)
  193. Resolving Binding Events on the Multifunctional Human Serum Albumin. Wenskowsky L, Wagner M, Reusch J, Schreuder H, Matter H, Opatz T, Petry SM. ChemMedChem 15 738-743 (2020)
  194. A concise approach to 1,11-didechloro-6-methyl-4'-O-demethyl rebeccamycin and its binding to human serum albumin: fluorescence spectroscopy and molecular modeling method. Cui F, Qin L, Zhang G, Liu X, Yao X, Lei B. Bioorg Med Chem 16 7615-7621 (2008)
  195. Combination of chiroptical, absorption and fluorescence spectroscopic methods reveals multiple, hydrophobicity-driven human serum albumin binding of the antimalarial atovaquone and related hydroxynaphthoquinone compounds. Zsila F, Fitos I. Org Biomol Chem 8 4905-4914 (2010)
  196. Evidence for pH-dependent multiple conformers in iron(II) heme-human serum albumin: spectroscopic and kinetic investigation of carbon monoxide binding. Cao Y, Nicoletti FP, De Sanctis G, Bocedi A, Ciaccio C, Gullotta F, Fanali G, Tundo GR, di Masi A, Fasano M, Smulevich G, Ascenzi P, Coletta M. J Biol Inorg Chem 17 133-147 (2012)
  197. Formation of protein/surfactant adsorption layer at the air/water interface as studied by dilational surface rheology. Mikhailovskaya AA, Noskov BA, Lin SY, Loglio G, Miller R. J Phys Chem B 115 9971-9979 (2011)
  198. Human serum albumin: A modulator of cannabinoid drugs. Leboffe L, di Masi A, Trezza V, Polticelli F, Ascenzi P. IUBMB Life 69 834-840 (2017)
  199. Ibuprofen and warfarin modulate allosterically ferrous human serum heme-albumin nitrosylation. Ascenzi P, Cao Y, Tundo GR, Coletta M, Fanali G, Fasano M. Biochem Biophys Res Commun 411 185-189 (2011)
  200. Interaction of bovine serum albumin with N-acyl amino acid based anionic surfactants: Effect of head-group hydrophobicity. Ghosh S, Dey J. J Colloid Interface Sci 458 284-292 (2015)
  201. Novel 7-(dimethylamino)fluorene-based fluorescent probes and their binding to human serum albumin. Park KK, Park JW, Hamilton AD. Org Biomol Chem 7 4225-4232 (2009)
  202. Novel hydrophobic interaction chromatography matrix for specific isolation and simple elution of immunoglobulins (A, G, and M) from porcine serum. Ramos-Clamont G, del Carmen Candia-Plata M, Zamudio RG, Vazquez-Moreno L. J Chromatogr A 1122 28-34 (2006)
  203. Paclitaxel binding to the fatty acid-induced conformation of human serum albumin--automated docking studies. Paal K, Shkarupin A. Bioorg Med Chem 15 7568-7575 (2007)
  204. Potent anticancer activity of cystine-based dipeptides and their interaction with serum albumins. Banerji B, Pramanik SK, Pal U, Maiti NC. Chem Cent J 7 91 (2013)
  205. Probing deuterium isotope effect on structure and solvation dynamics of human serum albumin. Das DK, Mondal T, Mandal U, Bhattacharyya K. Chemphyschem 12 814-822 (2011)
  206. Probing the binding site characteristics of HSA: a combined molecular dynamics and cheminformatics investigation. Pongprayoon P, Gleeson MP. J Mol Graph Model 54 164-173 (2014)
  207. Resveratrol induces thermal stabilization of human serum albumin and modulates the early aggregation stage. Stirpe A, Pantusa M, Rizzuti B, De Santo MP, Sportelli L, Bartucci R, Guzzi R. Int J Biol Macromol 92 1049-1056 (2016)
  208. Stress can affect drug pharmacokinetics via serum/tissues protein binding and blood flow rate alterations. Antonia K, Anastasia A, Tesseromatis C. Eur J Drug Metab Pharmacokinet 37 1-7 (2012)
  209. Structural evidence of the species-dependent albumin binding of the modified cyclic phosphatidic acid with cytotoxic properties. Sekula B, Ciesielska A, Rytczak P, Koziołkiewicz M, Bujacz A. Biosci Rep 36 e00338 (2016)
  210. The effect of serum albumin on amphotericin B aggregate structure and activity. Hartsel SC, Bauer E, Kwong EH, Wasan KM. Pharm Res 18 1305-1309 (2001)
  211. 2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer. Akinboye ES, Rogers OC, Isaacs JT. Prostate 78 655-663 (2018)
  212. A deoxygenation system for measuring protein phosphorescence. Banks DD, Kerwin BA. Anal Biochem 324 106-114 (2004)
  213. A simplified representation of anisotropic charge distributions within proteins. Hoppe T. J Chem Phys 138 174110 (2013)
  214. Assessment of new cationic porphyrin binding to plasma proteins by planar microarray and spectroscopic methods. Gyulkhandanyan A, Gyulkhandanyan L, Ghazaryan R, Fleury F, Angelini M, Gyulkhandanyan G, Sakanyan V. J Biomol Struct Dyn 31 363-375 (2013)
  215. Cantharidin inhibits competitively heme-Fe(III) binding to the FA1 site of human serum albumin. Polticelli F, Leboffe L, Tortosa V, Trezza V, Fanali G, Fasano M, Ascenzi P. J Mol Recognit 30 (2017)
  216. Computational Analysis of the Binding Mechanism of GenX and HSA. Delva-Wiley J, Jahan I, Newman RH, Zhang L, Dong M. ACS Omega 6 29166-29170 (2021)
  217. Conformation and Aggregation of Human Serum Albumin in the Presence of Green Tea Polyphenol (EGCg) and/or Palmitic Acid. Sun X, Ferguson HN, Hagerman AE. Biomolecules 9 E705 (2019)
  218. Crystal structure analysis of human serum albumin complexed with sodium 4-phenylbutyrate. Kawai A, Yamasaki K, Enokida T, Miyamoto S, Otagiri M. Biochem Biophys Rep 13 78-82 (2018)
  219. Deciphering the binding behaviours of BSA using ionic AIE-active fluorescent probes. Tong J, Hu T, Qin A, Sun JZ, Tang BZ. Faraday Discuss 196 285-303 (2017)
  220. Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer. Gou Y, Zhang Y, Qi J, Chen S, Zhou Z, Wu X, Liang H, Yang F. Oncotarget 7 67004-67019 (2016)
  221. Drug-protein interactions in micellar media: thermodynamic aspects. Choudhary S, Kishore N. J Colloid Interface Sci 413 118-126 (2014)
  222. Fluorescent probe mimicking multiple logic gates and a molecular keypad lock upon interaction with Hg2+ and bovine serum albumin. Misra A, Srivastava P, Shahid M. Analyst 137 3470-3478 (2012)
  223. GA/GB fold switching may modulate fatty acid transfer from human serum albumin to bacteria. Polticelli F, Caprari S, Gianni S, Ascenzi P. IUBMB Life 64 885-888 (2012)
  224. Genetically Encoding a Lipidated Amino Acid for Extension of Protein Half-Life in vivo. Fu C, Chen Q, Zheng F, Yang L, Li H, Zhao Q, Wang X, Wang L, Wang Q. Angew Chem Int Ed Engl 58 1392-1396 (2019)
  225. In-Vitro and In-Silico Assessment of Per- and Polyfluoroalkyl Substances (PFAS) in Aqueous Film-Forming Foam (AFFF) Binding to Human Serum Albumin. Li W, Hu Y, Bischel HN. Toxics 9 63 (2021)
  226. Influence of stearic acids on resveratrol-HSA interaction. Pantusa M, Sportelli L, Bartucci R. Eur Biophys J 41 969-977 (2012)
  227. Interaction of bovine serum albumin (BSA) with ionic surfactants evaluated by electron paramagnetic resonance (EPR) spectroscopy. de Sousa Neto D, Salmon CE, Alonso A, Tabak M. Colloids Surf B Biointerfaces 70 147-156 (2009)
  228. Molecular mechanism by which palmitate inhibits PKR autophosphorylation. Cho H, Mukherjee S, Palasuberniam P, Pillow L, Bilgin B, Nezich C, Walton SP, Feig M, Chan C. Biochemistry 50 1110-1119 (2011)
  229. Physiological concentrations of albumin favor drug binding. Tatlidil D, Ucuncu M, Akdogan Y. Phys Chem Chem Phys 17 22678-22685 (2015)
  230. Redox properties and human serum albumin binding of nitro-oleic acid. Zatloukalova M, Mojovic M, Pavicevic A, Kabelac M, Freeman BA, Pekarova M, Vacek J. Redox Biol 24 101213 (2019)
  231. Synthesis of an octupolar compound and its biological effects on serum albumin. Zhang HX, Gao S, Yang XX. Mol Biol Rep 36 1405-1411 (2009)
  232. The pentameric channel of COMPcc in complex with different fatty acids. McFarlane A, Orriss G, Okun N, Meier M, Klonisch T, Khajehpour M, Stetefeld J. PLoS One 7 e48130 (2012)
  233. Unveiling the binding mode of perfluorooctanoic acid to human serum albumin. Maso L, Trande M, Liberi S, Moro G, Daems E, Linciano S, Sobott F, Covaceuszach S, Cassetta A, Fasolato S, Moretto LM, De Wael K, Cendron L, Angelini A. Protein Sci 30 830-841 (2021)
  234. A two-step strategy to enhance activity of low potency peptides. Doyle JR, Harwood BN, Krishnaji ST, Krishnamurthy VM, Lin WE, Fortin JP, Kumar K, Kopin AS. PLoS One 9 e110502 (2014)
  235. Adsorption and adhesion of common serum proteins to nanotextured gallium nitride. Bain LE, Hoffmann MP, Bryan I, Collazo R, Ivanisevic A. Nanoscale 7 2360-2365 (2015)
  236. Analysis of binding interaction between the natural apocarotenoid bixin and human serum albumin by circular dichroism and fluorescence spectroscopy. Zsila F, Molnár P, Deli J. Chem Biodivers 2 758-772 (2005)
  237. Anticancer potency of small linear and cyclic tetrapeptides and pharmacokinetic investigations of peptide binding to human serum albumin. Sivertsen A, Tørfoss V, Isaksson J, Ausbacher D, Anderssen T, Brandsdal BO, Havelkova M, Skjørholm AE, Strøm MB. J Pept Sci 20 279-291 (2014)
  238. Application of maximum bubble pressure surface tensiometer to study protein-surfactant interactions. Dixit N, Zeng DL, Kalonia DS. Int J Pharm 439 317-323 (2012)
  239. Biophysical studies on the interactions of jatrorrhizine with bovine serum albumin by spectroscopic and molecular modeling methods. Mi R, Li PQ, Hu YJ, Fan XY, Li HY, Yu XC, Ouyang Y. Mol Biol Rep 40 4397-4404 (2013)
  240. Dissecting the Interactions between Chlorin e6 and Human Serum Albumin. Marconi A, Mattioli EJ, Ingargiola F, Giugliano G, Marforio TD, Prodi L, Di Giosia M, Calvaresi M. Molecules 28 2348 (2023)
  241. Effect of Temperature on Tolbutamide Binding to Glycated Serum Albumin. Szkudlarek A, Pentak D, Ploch A, Pożycka J, Maciążek-Jurczyk M. Molecules 22 E569 (2017)
  242. Effect of an ionic liquid on the unfolding of human serum albumin: a fluorescence correlation spectroscopy study. Das DK, Kumar Das A, Kumar Mandal A, Mondal T, Bhattacharyya K. Chemphyschem 13 1949-1955 (2012)
  243. Fatty acids bound to human serum albumin and its structural variants modulate apolipoprotein B secretion in HepG2 cells. Ha JS, Theriault A, Bhagavan NV, Ha CE. Biochim Biophys Acta 1761 717-724 (2006)
  244. Modulation of linoleic acid-binding properties of human serum albumin by divalent metal cations. Nemashkalova EL, Permyakov EA, Permyakov SE, Litus EA. Biometals 30 341-353 (2017)
  245. Multifunctional polypeptide-PEO nanoreactors via the hydrophobic switch. Wu Y, Wang T, Ng DY, Weil T. Macromol Rapid Commun 33 1474-1481 (2012)
  246. Protein-binding properties of a designed steroidal lactam compound. Zhang HX, Liu Y. Steroids 80 30-36 (2014)
  247. Stearic acid solubility and cubic phase volume. Schmidt WF, Barone JR, Francis B, Reeves JB. Chem Phys Lipids 142 23-32 (2006)
  248. Studies on the synthesis, characterization, human serum albumin binding and biological activity of single chain surfactant-cobalt(III) complexes. Vignesh G, Sugumar K, Arunachalam S, Vignesh S, Arthur James R, Arun R, Premkumar K. Luminescence 31 523-532 (2016)
  249. Synthesis of morin-zinc(II) complex and its interaction with serum albumin. Zhang HX, Mei P. Biol Trace Elem Res 143 677-687 (2011)
  250. Temperature-induced conformational transition of bovine serum albumin in neutral aqueous solution by reversed-phase liquid chromatography. Bian L, Wu D, Hu W. Biomed Chromatogr 28 295-301 (2014)
  251. Triantennary GalNAc Molecular Imaging Probes for Monitoring Hepatocyte Function in a Rat Model of Nonalcoholic Steatohepatitis. Mishra A, Castañeda TR, Bader E, Elshorst B, Cummings S, Scherer P, Bangari DS, Loewe C, Schreuder H, Pöverlein C, Helms M, Jones S, Zech G, Licher T, Wagner M, Schudok M, de Hoop M, Plowright AT, Atzrodt J, Kannt A, Laitinen I, Derdau V. Adv Sci (Weinh) 7 2002997 (2020)
  252. Tyrosine fluorescence probing of conformational changes in tryptophan-lacking domain of albumins. Zhdanova NG, Maksimov EG, Arutyunyan AM, Fadeev VV, Shirshin EA. Spectrochim Acta A Mol Biomol Spectrosc 174 223-229 (2017)
  253. X-ray crystallographic and fluorometric analysis of the interactions of rhein to human serum albumin. Li M, Lee P, Zhang Y, Ma Z, Yang F, Zhou Z, Wu X, Liang H. Chem Biol Drug Des 83 167-173 (2014)
  254. In Silico Docking of Alkylphosphocholine Analogs to Human Serum Albumin Predicts Partitioning and Pharmacokinetics. Zhang RR, Grudzinksi JJ, Mehta TI, Burnette RR, Hernandez R, Clark PA, Lubin JA, Pinchuk AN, Jeffrey J, Longino M, Kuo JS, Weichert JP. Mol Pharm 16 3350-3360 (2019)
  255. Alterations in conformational state of albumin in plasma in chronic hemodialyzed patients. Pieniazek A, Gwozdzinski L, Zbrog Z, Gwozdzinski K. PLoS One 13 e0192268 (2018)
  256. Binding of organic dyes with human serum albumin: a single-molecule study. Das DK, Mondal T, Mandal AK, Bhattacharyya K. Chem Asian J 6 3097-3103 (2011)
  257. Binding site multiplicity with fatty acid ligands: implications for the regulation of PKR kinase autophosphorylation with palmitate. Fang L, Cho HJ, Chan C, Feig M. Proteins 82 2429-2442 (2014)
  258. Computational study of ligand binding to protein receptors. Wembridge P, Robinson H, Novak I. Bioorg Chem 36 288-294 (2008)
  259. Cross-linked human serum albumin dimer has the potential for use as a plasma-retaining agent for the fatty acid-conjugated antidiabetic drugs. Taguchi K, Chuang VT, Chuang VT, Yamasaki K, Urata Y, Tanaka R, Anraku M, Seo H, Kawai K, Maruyama T, Komatsu T, Otagiri M. J Pharm Pharmacol 67 255-263 (2015)
  260. Efficient identification of photolabelled amino acid residues by combining immunoaffinity purification with MS: revealing the semotiadil-binding site and its relevance to binding sites for myristates in domain III of human serum albumin. Kawahara K, Kuniyasu A, Masuda K, Ishiguro M, Nakayama H. Biochem J 363 223-232 (2002)
  261. Inhibition of Amyloid Aggregation of Bovine Serum Albumin by Sodium Dodecyl Sulfate at Submicellar Concentrations. Ma XJ, Zhang YJ, Zeng CM. Biochemistry (Mosc) 83 60-68 (2018)
  262. Interaction of Conazole Pesticides Epoxiconazole and Prothioconazole with Human and Bovine Serum Albumin Studied Using Spectroscopic Methods and Molecular Modeling. Golianová K, Havadej S, Verebová V, Uličný J, Holečková B, Staničová J. Int J Mol Sci 22 1925 (2021)
  263. Lipoic Acid Restores Binding of Zinc Ions to Human Serum Albumin. Al-Harthi S, Chandra K, Jaremko Ł. Front Chem 10 942585 (2022)
  264. Lysine reactivity profiling reveals molecular insights into human serum albumin-small-molecule drug interactions. Yang S, Zhang W, Liu Z, Zhai Z, Hou X, Wang P, Ge G, Wang F. Anal Bioanal Chem 413 7431-7440 (2021)
  265. Microheterogeneity in frozen protein solutions. Twomey A, Kurata K, Nagare Y, Takamatsu H, Aksan A. Int J Pharm 487 91-100 (2015)
  266. Predicting the activity and toxicity of new psychoactive substances: a pharmaceutical industry perspective. Leach AG. Drug Test Anal 6 739-745 (2014)
  267. Revealing the role of oxidation state in interaction between nitro/amino-derived particulate matter and blood proteins. Liu Z, Li P, Bian W, Yu J, Zhan J. Sci Rep 6 25909 (2016)
  268. Self-Propelled Soft Protein Microtubes with a Pt Nanoparticle Interior Surface. Kobayakawa S, Nakai Y, Akiyama M, Komatsu T. Chemistry 23 5044-5050 (2017)
  269. Site-Specific Lipidation of a Small-Sized Protein Binder Enhances the Antitumor Activity through Extended Blood Half-Life. Kim TY, Nam YR, Park JH, Lee DE, Kim HS. ACS Omega 5 19778-19784 (2020)
  270. Unraveling the Stability of Plasma Proteins upon Interaction of Synthesized Androstenedione and Its Derivatives-A Biophysical and Computational Approach. Nerusu A, Reddy PS, Ramachary DB, Subramanyam R. ACS Omega 2 6514-6524 (2017)
  271. A differential vapor-pressure equipment for investigations of biopolymer interactions. Andersen KB, Koga Y, Westh P. J Biochem Biophys Methods 50 269-288 (2002)
  272. An Escherichia coli trap in human serum albumin microtubes. Yuge S, Akiyama M, Komatsu T. Chem Commun (Camb) 50 9640-9643 (2014)
  273. Antioxidant Activity Evaluation and Assessment of the Binding Affinity to HSA of a New Catechol Hydrazinyl-Thiazole Derivative. Mic M, Pîrnău A, Floare CG, Borlan R, Focsan M, Oniga O, Bogdan M, Vlase L, Oniga I, Marc G. Antioxidants (Basel) 11 1245 (2022)
  274. Binding of anti-cardiovascular drug to serum albumin: an insight in the light of spectroscopic and computational approaches. Chandel TI, Rabbani G, Khan M, Zaman M, Alam P, E Shahein Y, Hasan Khan R. J Biomol Struct Dyn 36 54-67 (2018)
  275. Changes in the electron paramagnetic resonance spectra of albumin-associated spin-labeled stearic acid as a diagnostic parameter of colorectal cancer. Liu Z, Zhang W, Fan S, Wang L, Jiao L. World J Surg Oncol 11 223 (2013)
  276. Characterization of binding between model protein GA-Z and human serum albumin using asymmetrical flow field-flow fractionation and small angle X-ray scattering. Choi J, Wahlgren M, Ek V, Elofsson U, Fransson J, Nilsson L, Terry A, Söderberg CAG. PLoS One 15 e0242605 (2020)
  277. Combined fluorescence and electrochemical investigation on the binding interaction between organic acid and human serum albumin. Chen YM, Guo LH. J Environ Sci (China) 21 373-379 (2009)
  278. Exploring the binding of 4-thiothymidine with human serum albumin by spectroscopy, atomic force microscopy, and molecular modeling methods. Zhang J, Gu H, Zhang X. Carbohydr Res 384 102-111 (2014)
  279. Far-red pentamethine cyanine dyes as fluorescent probes for the detection of serum albumins. Aristova D, Volynets G, Chernii S, Losytskyy M, Balanda A, Slominskii Y, Mokhir A, Yarmoluk S, Kovalska V. R Soc Open Sci 7 200453 (2020)
  280. Human serum albumin binding to silica nanoparticles--effect of protein fatty acid ligand. Ang JC, Henderson MJ, Campbell RA, Lin JM, Yaron PN, Nelson A, Faunce T, White JW. Phys Chem Chem Phys 16 10157-10168 (2014)
  281. Lipid-conjugated Smac analogues. Micewicz ED, Ratikan JA, Waring AJ, Whitelegge JP, McBride WH, Ruchala P. Bioorg Med Chem Lett 25 4419-4427 (2015)
  282. Molecular Basis for the Selectivity of DHA and EPA in Sudlow's Drug Binding Sites in Human Serum Albumin with the Combined Use of NMR and Docking Calculations. Alexandri E, Venianakis T, Primikyri A, Papamokos G, Gerothanassis IP. Molecules 28 3724 (2023)
  283. Role of PAMAM-OH dendrimers against the fibrillation pathway of biomolecules. Sekar G, Florance I, Sivakumar A, Mukherjee A, Chandrasekaran N. Int J Biol Macromol 93 1007-1018 (2016)
  284. Short-chain lipid-conjugated pH sensors for imaging of transporter activities in reconstituted systems and living cells. Kühnel RM, Grifell-Junyent M, Jørgensen IL, Kemmer GC, Schiller J, Palmgren M, Justesen BH, Günther Pomorski T. Analyst 144 3030-3037 (2019)
  285. Structural determinants of binding of aromates to extracellular matrix: a multi-species multi-mode CoMFA study. Zhang Y, Lukacova V, Bartus V, Balaz S. Chem Res Toxicol 20 11-19 (2007)
  286. The Effect of Fatty Acids and BSA Purity on Synthesis and Properties of Fluorescent Gold Nanoclusters. Andrýsková P, Šišková KM, Michetschlägerová Š, Jiráková K, Kubala M, Jirák D. Nanomaterials (Basel) 10 E343 (2020)
  287. The Release of a Highly Cytotoxic Paullone Bearing a TEMPO Free Radical from the HSA Hydrogel: An EPR Spectroscopic Characterization. Vesković A, Nakarada Đ, Vasiljević O, Dobrov A, Spengler G, Enyedy ÉA, Arion VB, Popović Bijelić A. Pharmaceutics 14 1174 (2022)
  288. The binding properties of metandienone and human serum albumin by comparing with other five similar compounds. Lin X, Wang Q, Peng X, Li H. J Biochem Mol Toxicol 31 (2017)
  289. The interplay between copper(II), human serum albumin, fatty acids, and carbonylating agent interferes with Cys 34 thiol reactivity and copper binding. Penezić AZ, Aćimović JM, Pavićević ID, Jovanović VB, Takić M, Mandić LM. J Biol Inorg Chem 24 61-70 (2019)
  290. The lipid components of high-density lipoproteins (HDL) are essential for the binding and transportation of antimicrobial peptides in human serum. Tang WH, Wang SH, Wang CF, Mou Y, Lin MG, Hsiao CD, Liao YD. Sci Rep 12 2576 (2022)
  291. AlbuCORE: an albumin-based molecular scaffold for multivalent biologics design. Sanches M, D'Angelo I, Jaramillo M, Baardsnes J, Zwaagstra J, Schrag J, Schoenhofen I, Acchione M, Lawn S, Wickman G, Weisser N, Poon DKY, Ng G, Dixit S. MAbs 12 1802188 (2020)
  292. Albumin Lipidomics Reveals Meaningful Compositional Changes in Advanced Cirrhosis and Its Potential to Promote Inflammation Resolution. Casulleras M, Flores-Costa R, Duran-Güell M, Zhang IW, López-Vicario C, Curto A, Fernández J, Arroyo V, Clària J. Hepatol Commun 6 1443-1456 (2022)
  293. Antidepressant drug-protein interactions studied by spectroscopic methods based on fluorescent carbon quantum dots. Reshma, Vaishanav SK, Yadav T, Sinha S, Tiwari S, Satnami ML, Ghosh KK. Heliyon 5 e01631 (2019)
  294. Biochemical evaluation of a synthesized isoflavone-selenium complex by molecular spectra. Zhang HX, Huang ZX. Mol Biol Rep 39 7457-7463 (2012)
  295. Calcium inhibits diacylglycerol uptake by serum albumin. Ahyayauch H, Arana G, Sot J, Alonso A, Goñi FM. Biochim Biophys Acta 1788 701-707 (2009)
  296. Comparison and analysis on the serum-binding characteristics of aspirin-zinc complex and aspirin. Zhang HX, Zhang Q, Wang HL, Li LW. Luminescence 32 1017-1024 (2017)
  297. Comparison of binding characterization of two antiviral drugs to human serum albumin. Li M, McAuley E, Zhang Y, Kong L, Yang F, Zhou Z, Wu X, Liang H. Chem Biol Drug Des 83 576-582 (2014)
  298. Computational design and genetic incorporation of lipidation mimics in living cells. Ding W, Liu C, Chen Y, Gu J, Fang C, Hu L, Zhang L, Yuan Y, Feng XH, Lin S. Nat Chem Biol (2023)
  299. Conformational changes and allosteric communications in human serum albumin due to ligand binding. Ahalawat N, Murarka RK. J Biomol Struct Dyn 33 2192-2204 (2015)
  300. Insights into molecular medicine: development of new diagnostic and prognostic parameters. Tilz GP, Wiltgen M, Demel U, Faschinger C, Schmidinger H, Hermetter A. Wien Med Wochenschr 157 122-129 (2007)
  301. Interaction of Aggregated Cationic Porphyrins with Human Serum Albumin. Samperi M, Vittorio S, De Luca L, Romeo A, Monsù Scolaro L. Int J Mol Sci 24 2099 (2023)
  302. Molecular phylogenetic analyses of albuminoids reveal the molecular evolution of allosteric properties. Ascenzi P, di Masi A, Leboffe L, Alberio T, Fanali G, Fasano M. IUBMB Life 65 544-549 (2013)
  303. Structural Basis of Artemisinin Binding Sites in Serum Albumin with the Combined Use of NMR and Docking Calculations. Primikyri A, Papamokos G, Venianakis T, Sakka M, Kontogianni VG, Gerothanassis IP. Molecules 27 5912 (2022)
  304. Structural Studies of Monounsaturated and ω-3 Polyunsaturated Free Fatty Acids in Solution with the Combined Use οf NMR and DFT Calculations-Comparison with the Liquid State. Venianakis T, Siskos MG, Papamokos G, Gerothanassis IP. Molecules 28 6144 (2023)
  305. Structural and biochemical characterisation of Co2+-binding sites on serum albumins and their interplay with fatty acids. Wu D, Gucwa M, Czub MP, Cooper DR, Shabalin IG, Fritzen R, Arya S, Schwarz-Linek U, Blindauer CA, Minor W, Stewart AJ. Chem Sci 14 6244-6258 (2023)
  306. Surfactant displacement of human serum albumin adsorbed on loosely packed self-assembled monolayers: cetyltrimethylammonium bromide versus sodium dodecyl sulfate. Choi EJ, Foster MD. J Colloid Interface Sci 261 273-282 (2003)
  307. The Minimal Effect of Linker Length for Fatty Acid Conjugation to a Small Protein on the Serum Half-Life Extension. Cho J, Park J, Tae G, Jin MS, Kwon I. Biomedicines 8 E96 (2020)
  308. Understanding the biomimetic properties of gallium in Pseudomonas aeruginosa: an XAS and XPS study. Porcaro F, Bonchi C, Ugolini A, Frangipani E, Polzonetti G, Visca P, Meneghini C, Battocchio C. Dalton Trans 46 7082-7091 (2017)
  309. 3-Ferrocenyl-estra-1,3,5 (10)-triene-17-one: Synthesis, Crystal Structure, Hirshfeld Surface Analysis, DFT Studies, and Its Binding to Human Serum Albumin Studied through Fluorescence Quenching and In Silico Docking Studies. Flores-Rivera MM, Carmona-Negrón JA, Rheingold AL, Meléndez E. Molecules 28 6147 (2023)
  310. 4-Chloro-1,2-phenylenediamine induced structural perturbation and genotoxic aggregation in human serum albumin. Warsi MS, Habib S, Talha M, Khan S, Singh P, Mir AR, Abidi M, Ali A, Moinuddin. Front Chem 10 1016354 (2022)
  311. A Pd(II)-containing self-assembled macrocyclic host induces helical coiling of fatty acids. Lim CW, Le HT, Jung GS, Kim TW. Chemistry 19 1209-1212 (2013)
  312. Albumin Deficiency Reduces Hepatic Steatosis and Improves Glucose Metabolism in a Mouse Model of Diet-Induced Obesity. Abdollahi A, Narayanan SK, Frankovich A, Lai YC, Zhang Y, Henderson GC. Nutrients 15 2060 (2023)
  313. Albumin-based nanoparticles: small, uniform and reproducible. Thalhammer-Thurner GC, Debbage P. Nanoscale Adv 5 503-512 (2023)
  314. Crystal structures of human serum albumin in complex with lysophosphatidylcholine. Wang Y, Luo Z, Morelli X, Xu P, Jiang L, Shi X, Huang M. Biophys J 122 4135-4143 (2023)
  315. Dopamine-Conjugated Bovine Serum Albumin Nanoparticles Containing pH-Responsive Catechol-V(III) Coordination for In Vitro and In Vivo Drug Delivery. Argitekin E, Ersoz-Gulseven E, Cakan-Akdogan G, Akdogan Y. Biomacromolecules 24 3603-3618 (2023)
  316. Effects of Myristate on the Induced Circular Dichroism Spectra of Aripiprazole Bound to Human Serum Albumin: A Structural-Chemical Investigation. Hirata K, Kawai A, Chuang VTG, Sakurama K, Nishi K, Yamasaki K, Otagiri M. ACS Omega 7 4413-4419 (2022)
  317. Exploring Albumin Functionality Assays: A Pilot Study on Sepsis Evaluation in Intensive Care Medicine. Klinkmann G, Waterstradt K, Klammt S, Schnurr K, Schewe JC, Wasserkort R, Mitzner S. Int J Mol Sci 24 12551 (2023)
  318. Impact of hyperlipidaemia on the orbital bone cefotaxime levels in rats. Panitsa G, Panitsas A, Potamianou A, Messari J, Vovou J, Tesseromatis C. Eur J Drug Metab Pharmacokinet 35 23-27 (2010)
  319. Interactive multiple binding of oleic acid, warfarin and ibuprofen with human serum albumin revealed by thermal and fluorescence studies. Guzzi R, Bartucci R. Eur Biophys J 51 41-49 (2022)
  320. Interpreting physicochemical experimental data sets. Colclough N, Wenlock MC. J Comput Aided Mol Des 29 779-794 (2015)
  321. Modification of the structural stability of human serum albumin in rheumatoid arthritis. Lin HL, Parkinson DH, Holman JC, Thompson WC, Anderson CNK, Hadfield M, Ames S, Zuniga Pina NR, Bowden JN, Quinn C, Hansen LD, Price JC. PLoS One 18 e0271008 (2023)
  322. NMR and Docking Calculations Reveal Novel Atomistic Selectivity of a Synthetic High-Affinity Free Fatty Acid vs. Free Fatty Acids in Sudlow's Drug Binding Sites in Human Serum Albumin. Venianakis T, Primikyri A, Opatz T, Petry S, Papamokos G, Gerothanassis IP. Molecules 28 7991 (2023)
  323. Neutron study of phospholipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-ethanolamine spray coating on titanium implants. Golub M, Lott D, Garamus VM, Laipple D, Stoermer M, Watkins EB, Schreyer A, Willumeit-Römer R. Biointerphases 11 011002 (2015)
  324. Novel rare earth tungstoarsenate heteropolyoxometalates K11[Ln(AsW 11O 39) 2]·xH 2O (Ln = La, Nd, Sm) binding to bovine serum albumin: spectroscopic approach. Jiang S, Cheng LY, Bai AM, Zhou S, Hu YJ. Biol Trace Elem Res 163 275-282 (2015)
  325. Optimizing Excipient Properties to Prevent Aggregation in Biopharmaceutical Formulations. King TE, Humphrey JR, Laughton CA, Thomas NR, Hirst JD. J Chem Inf Model 64 265-275 (2024)
  326. Porphyrin-loaded liposomes and graphene oxide used for the membrane pore-forming protein assay and inhibitor screening. Liu Z, Long T, Wu S, Li C. Analyst 140 5495-5500 (2015)
  327. Position of lipidation influences anticancer activity of Smac analogs. Micewicz ED, Nguyen C, Micewicz A, Waring AJ, McBride WH, Ruchala P. Bioorg Med Chem Lett 29 1628-1635 (2019)
  328. Protein classification using comparative molecular interaction profile analysis system. Hayashi Y, Kobayashi M, Sakaguchi K, Iwata N, Kobayashi M, Kikuchi Y, Takahashi Y. J Bioinform Comput Biol 2 497-510 (2004)
  329. Quantification of Interactions between Serum Albumin and Endogenous Free Fatty Acids or Exogenous Chemicals by Stable Isotope-Coded Mass Spectrometry. Li T, Yue Y, Li J, Wang X, Fu J, Zhong H. ACS Med Chem Lett 2 587-591 (2011)
  330. Role of Thylakoid Lipids in Protochlorophyllide Oxidoreductase Activation: Allosteric Mechanism Elucidated by a Computational Study. Liu R, Wang L, Meng Y, Li F, Nie H, Lu H. Int J Mol Sci 24 307 (2022)
  331. Stratiform Protein Microtube Reactors Containing Glucose Oxidase Layer. Adachi R, Akiyama M, Morita Y, Komatsu T. Chem Asian J 13 2796-2799 (2018)
  332. Structural Investigation of Diclofenac Binding to Ovine, Caprine, and Leporine Serum Albumins. Talaj JA, Zielinski K, Bujacz A. Int J Mol Sci 24 1534 (2023)
  333. Transient coating of γ-Fe2O3 nanoparticles with glutamate for its delivery to and removal from brain nerve terminals. Paliienko K, Pastukhov A, Babič M, Horák D, Vasylchenko O, Borisova T. Beilstein J Nanotechnol 11 1381-1393 (2020)


Quick links